Objective: Non-muscle-invasive high-grade (T1G3) bladder cancers have high potential for progression. The objective of this study is to clarify the clinicopathological factors affecting the outcome of T1G3 bladder cancer. Methods: We retrospectively reviewed 60 cases of T1G3 bladder cancer between 1994 and 2006. The correlations of both intravesical recurrence and progression with prognostic factors, such as T stage, history of bladder cancer, multiplicity, concomitant carcinoma in situ, tumor size, intravesical instillation of bacillus Calmette -Gué rin and intravesical chemotherapy, were evaluated by multivariate analysis with the Cox proportional hazards model. Results: Median follow-up period was 52 months (4 -105 months). Thirty-seven cases of intravesical recurrence (61.7%) were observed during follow-up. Two-and 5-year recurrencefree survival rates were 44.1% and 36.1%, respectively. Tumor multiplicity and instillation of bacillus Calmette -Gué rin were significantly correlated with intravesical recurrence on multivariate analysis. Ten cases of progression (16.7%) were observed during the follow-up period. Two-and 5-year progression-free survival rates were 87.7% and 83.4%, respectively. Only tumor multiplicity was significantly correlated with progression on multivariate analysis. Conclusions: T1G3 cancers with multiple lesions showed high risks of intravesical recurrence and progression. Although bacillus Calmette -Gué rin instillation reduced the risk of intravesical recurrence, no effect was observed on disease progression.
INTRODUCTION
About 70% of patients with newly diagnosed bladder cancer present with superficial non-muscle-invasive urothelial carcinoma. The majority of these lesions are not life-threatening and can be managed conservatively. However, some not only recur intravesically but also progress to muscle-invasive urothelial carcinoma (1) . Muscle-invasive urothelial cancer is often life-threatening and requires more aggressive treatment. Therefore, predicting the risks of recurrence and progression at the time of diagnosis would be useful for optimal management of superficial bladder cancer. Sylvester et al. (2) analyzed 2596 patients from seven European Organisation for Research and Treatment of Cancer trials and established a scoring system in non-muscle-invasive bladder cancer with multifocal disease, concomitant carcinoma in situ (cis) and tumor size .3 cm as factors predicting the risk of recurrence and progression. According to this scoring system, Grade 3 bladder cancer has very high weighing for disease progression.
Non-muscle-invasive high-grade (T1G3) bladder cancer accounts for roughly 10% of all non-muscle-invasive bladder cancers. T1G3 bladder cancers should be considered a crucial disease entity because they have high potential for progression and eventually cancer death (3) . When treated by transurethral resection of the bladder (TURB) alone, the recurrence rate is 50 -80% and progression to muscle-invasive disease occurs in 27 -63% of patients (4) . There is still debate regarding the most appropriate form of management for T1G3 bladder cancer; i.e. immediate cystectomy or conservative management, such as intravesical instillation of bacillus Calmette -Guérin (BCG). There are marked differences in terms of quality of life (QOL) between early cystectomy and conservative management, and therefore, it is necessary to determine prognostic factors to help distinguish cases that should be managed aggressively by early cystectomy.
In this study, we analyzed the clinical outcomes of 60 patients with T1G3 bladder cancer managed conservatively along with the clinicopathological factors that may affect the risks of disease recurrence and progression.
PATIENTS AND METHODS
From January 1994 to June 2006, we encountered 73 bladder cancer patients with T1G3 component, 63 of them were treated conservatively. Three of the cases were excluded from this study because of short follow-up period. Complete TURB tumor was performed until the muscular layer was exposed for each bladder cancer, and the lack of invasion to the muscularis was confirmed histologically. All patients underwent excretory urography, cytology and cystoscopy before TURB. When cytology was positive, random biopsy of the bladder and collection of urine from the upper urinary tract for cytological examination were performed. Repeat TURB for T1G3 tumors has become a common practice at our institution only since 2004, and it was not performed in the current series.
The patient characteristics are shown in Table 1 . Median follow-up period was 52 months (4 -105 months). Of a total of 60 cases, 42 had positive cytology, which is almost the same positive rate as the previous report (5) . About one-third of the patients had a history of non-muscle-invasive bladder cancer, and two cases had a history of more than five lesions. If there were other superficial bladder cancers at the same time with any grade, these cases were defined as multiple cases. The study population included 32 cases of multiple lesions and 13 cases had more than five lesions. There were six cases with concomitant cis. Seventeen patients had tumors .3 cm. In cases with multiple tumors, the largest lesions were not necessarily high-grade (G3) lesions.
With regard to adjuvant treatment, 17 patients received BCG instillation and 7 patients received intravesical chemotherapy. Thirty-six patients were treated by TUR alone. Instillation of BCG or anticancer agents was performed at the discretion of the physician in charge. Those who did not received any adjuvant treatment tended to be older patients and had small and/or less number of tumors. No maintenance BCG therapy was performed in this series. There were no differences in background between the cases with and without BCG instillation, such as sex, T category, history of bladder cancer, multiplicity or size; however, significantly more patients with concomitant cis received BCG instillation (P ¼ 0.00037).
Follow-up consisted of cystoscopy and cytology every 3 months for 2 years and every 6 months thereafter.
Recurrence was defined as intravesical recurrence at any grade and any T category. Progression was defined as recurrence of muscle-invasive bladder cancer (pT2, pT3 and pT4) and/or recurrence in the upper urinary tract. The date of recurrence or progression was the date of TUR or any other treatment for recurrent lesions. The final analysis of outcome was performed in July 2008. The observation period was censored at the time of last visit to the hospital for those who were lost of follow-up.
Risk factors analyzed in this study were determined based on EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder (7). Statistical analysis was performed using StatMate III (Avice, Tokyo, Japan). Differences were considered significant at P , 0.05. Recurrence-free survival and progression-free survival were estimated by the Kaplan -Meier method with significance evaluated by log-rank test. Univariate Cox's proportional hazards analysis was performed to analyze the predictive value of each risk factor for recurrence and progression. To control for confounding effects, multivariate Cox's proportional hazards analysis was also performed. The hazards were estimated based on the 95% confidence interval. 
RESULTS

INTRAVESICAL RECURRENCE
Thirty-seven patients (61.7%) showed intravesical recurrence. Two-and 5-year recurrence-free survival rates were 44.1% and 36.1%, respectively (Fig. 1a) . On univariate Cox's regression analysis, no co-variables showed significant correlations with intravesical recurrence (Table 2 ). However, multivariate Cox's regression analysis indicated that tumor multiplicity and BCG instillation were significantly correlated with intravesical recurrence (Table 3) . In both single and multiple tumor groups, BCG instillation tended to reduce intravesical recurrence (Fig. 1d) .
PROGRESSION
Ten patients (16.7%) showed progression in this series. Nine of the patients progressed to muscle-invasive bladder cancer and one showed occurrence in the upper urinary tract. No distant metastases were observed before progression. Twoand 5-year progression-free survival rates were 87.7% and 83.4%, respectively (Fig. 2a) . On univariate Cox's regression analysis, tumor multiplicity showed a correlation with progression with borderline P value (Table 4) . Multivariate Cox's regression analysis revealed that tumor multiplicity is an independent risk factor for progression (Table 5) . BCG instillation had no effect on reduction of progression in either the single or multiple tumor groups (Fig. 2d) .
OUTCOME OF THE PROGRESSED PATIENTS
Five of the 10 patients with tumor progression showed metastasis after progression and all 5 of these patients died from cancer. No patients died from other causes than bladder cancer. The median survival period after progression was 16 months (range 7 -35 months), and 2-and 5-year cancer- 
DISCUSSION
Approximately 10% of the patients with non-muscleinvasive bladder cancer have Grade 3 disease (3). Despite often being referred to as superficial, these tumors exhibit the histopathological, clinical and biological characteristics of invasive tumors (6) . There is still debate about the most appropriate treatment for non-muscle-invading grade 3 bladder cancer; i.e. immediate cystectomy or conservative management, such as intravesical instillation of BCG. The main difficulties in decision-making regarding management are due to the differences in QOL between early cystectomy and conservative management. Therefore, there is an urgent demand for patient risk stratification to identify which cases actually require aggressive treatment, such as cystectomy. In our series of T1G3 bladder cancer patients who were treated conservatively, we first examined the clinicopathological factors that affect intravesical recurrence. We chose five patient-related factors (T stage, history of bladder cancer, multiplicity, concomitant cis and tumor size) and two treatment-related factors (BCG instillation and intravesical chemotherapy). Univariate Cox's regression analysis indicated that intravesical chemotherapy had almost no effect on intravesical recurrence and we therefore omitted this factor from further multivariate Cox's regression analysis. Multivariate analysis indicated that tumor multiplicity and BCG instillation were independent risk factors for intravesical recurrence. Patients with multiple tumors may have had increased risk because the chances of incomplete resection and microscopic tumor dissemination increase with the number of tumors, and multifocality indicates the susceptibility of the entire urothelium to tumor development (i.e. the field effect) (8) . It is widely accepted that adjuvant intravesical BCG immunotherapy reduces the risk of recurrence for non-muscle-invasive bladder cancer. Four meta-analyses have confirmed that BCG after TURB is superior to TURB alone, or TURB and chemotherapy, in preventing intravesical recurrence (9 -12) . Our results confirmed the effects of BCG against intravesical recurrence even for selected patients with T1G3 bladder cancer. We next examined the clinicopathological factors that affect tumor progression. We chose the same factors as used in the analysis of intravesical recurrence. Again, intravesical chemotherapy had no effect on progression based on the results of univariate Cox's regression analysis, and it was omitted from further multivariate Cox's regression analysis. Multivariate analysis indicated that only tumor multiplicity was an independent risk factor for progression. The increased risk of progression in cases with multiple tumors may be because multifocal tumors tend to be underestimated in terms of T stage, which suggests a strong need for close follow-up of the bladder in patients receiving conservative management. In this series, we did not perform repeat TURB and we could not exclude the possibility of understaging of the disease.
We did not find any effect of BCG instillation on tumor progression. In comparison to intravesical recurrence, there have been few previous studies of the effects of BCG on progression and the results reported to date have been controversial. Individual studies of the effects of BCG on disease progression have mainly included patients with only moderate-risk disease, often with only a relatively short follow-up period where the number of cases of tumor progression was small (13) . Based on a meta-analysis of 24 studies, Sylvester et al. (14) reported that intravesical BCG, when followed by maintenance BCG treatment, reduced the odds of progression by 27% when compared with TURB alone. This study should be interpreted carefully because only 2% of the patients had Grade 3 bladder cancer, and observations applicable to non-muscle-invasive bladder cancer in general may not apply to Grade 3 disease. Shahin et al. (15) did not find any effect of BCG on tumor progression in an analysis of 153 non-muscle-invasive grade 3 bladder cancer patients. In our series, BCG did not reduce the risk of progression. As none of the patients received maintenance BCG therapy in our series, we could not exclude the possibility that maintenance BCG therapy would reduce the risk of disease progression. At present, the effect of BCG against progression in T1G3 bladder cancer is not conclusive.
Other reports have emphasized the importance of tumor multiplicity in T1G3 bladder cancer. Denzinger et al. (16) reported that multiplicity when combined with other risk factors, such as size and concomitant cis, could predict high risk of cancer-specific death. Similarly, Serretta et al. (17) recently reported that history and multiplicity are relevant predictors of survival in T1G3 tumors. In our series, we examined intravesical recurrence and tumor progression and concluded that patients with multiple tumors were at significantly elevated risk for both intravesical recurrence and progression. However, we did not analyze the factors affecting survival for the following two reasons. First, many factors, such as performance status, may influence the treatment decision after progression, which could affect the outcome of the disease. The second reason is that we could not reach definitive conclusions based on the results in only six patients who died from the disease. However, 5 of the 10 patients with progression died from the disease suggesting very poor prognosis after progression. Therefore, disease progression can be used as a surrogate for cancer death and 256 Impact of multiplicity in T1G3 bladder cancer our results support those of other studies suggesting that multiplicity is a factor that negatively affects long-term survival. Even though our series is relatively small compared with the recent outcome analysis of T1G3 bladder (16, 17) , multiple disease reached a statistical significance as an independent poor prognostic factor, which further strengthen the importance of multiple disease.
In conclusion, non-muscle-invasive grade 3 bladder cancers with multiple lesions have a high risk of intravesical recurrence and progression. Although BCG instillation reduced the risk of intravesical recurrence, it did not prevent disease progression. As the prognosis is very poor after progression, every effort should be made to reduce the likelihood of disease progression in these patients.
